Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History LGND

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics LGND

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield 0.11 %
Consecutive Years 0
Forward Annual Dividend 0.12 USD
Consistent Years 0
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date 02.07.2010

Ligand Pharmaceuticals Incorporated

LGND
Current price
113.76 USD -0.06 USD (-0.05%)
Last closed 114.58 USD
ISIN US53220K5048
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 210 729 472 USD
Yield for 12 month +30.94 %
1Y
3Y
5Y
10Y
15Y
LGND
21.11.2021 - 28.11.2021

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. Address: 555 Heritage Drive, Jupiter, FL, United States, 33458

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

143.88 USD

P/E Ratio

Dividend Yield

Financials LGND

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures LGND

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+167 133 000 USD

Last Year

+131 314 000 USD

Current Quarter

+45 333 000 USD

Last Quarter

+42 812 000 USD

Current Year

+156 059 000 USD

Last Year

+96 265 000 USD

Current Quarter

+40 484 000 USD

Last Quarter

+39 975 000 USD
EBITDA 18 157 000 USD
Operating Margin TTM -80.87 %
Price to Earnings
Return On Assets TTM -1.14 %
PEG Ratio 1.53
Return On Equity TTM -16.56 %
Wall Street Target Price 143.88 USD
Revenue TTM 181 488 000 USD
Book Value 41.27 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 46.30 %
Dividend Yield
Gross Profit TTM 102 908 000 USD
Earnings per share -7.29 USD
Diluted Eps TTM -7.29 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 103.20 %
Profit Margin -73.07 %

Stock Valuation LGND

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 18.98
Enterprise Value Revenue 10.91
Price Sales TTM 12.18
Enterprise Value EBITDA 19.13
Price Book MRQ 2.75

Technical Indicators LGND

For 52 Weeks

85.18 USD 129.90 USD
50 Day MA 108.23 USD
Shares Short Prior Month 1 228 133
200 Day MA 110.52 USD
Short Ratio 10.11
Shares Short 1 154 068
Short Percent 7.25 %